Foamix Pharmaceuticals (NASDAQ: FOMX) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare Foamix Pharmaceuticals to related businesses based on the strength of its risk, valuation, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for Foamix Pharmaceuticals and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foamix Pharmaceuticals 0 0 2 0 3.00
Foamix Pharmaceuticals Competitors 805 3165 11473 230 2.71

Foamix Pharmaceuticals currently has a consensus target price of $10.50, indicating a potential upside of 92.31%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.36%. Given Foamix Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Foamix Pharmaceuticals is more favorable than its peers.

Profitability

This table compares Foamix Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Foamix Pharmaceuticals -1,439.32% -54.81% -50.94%
Foamix Pharmaceuticals Competitors -5,381.56% -435.28% -40.64%

Volatility and Risk

Foamix Pharmaceuticals has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Foamix Pharmaceuticals’ peers have a beta of 1.88, indicating that their average stock price is 88% more volatile than the S&P 500.

Valuation and Earnings

This table compares Foamix Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Foamix Pharmaceuticals $5.53 million -$29.33 million -3.39
Foamix Pharmaceuticals Competitors $286.20 million $34.74 million 138.59

Foamix Pharmaceuticals’ peers have higher revenue and earnings than Foamix Pharmaceuticals. Foamix Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

58.8% of Foamix Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.